<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854202</url>
  </required_header>
  <id_info>
    <org_study_id>HCCBI 017-2008-112</org_study_id>
    <nct_id>NCT02854202</nct_id>
  </id_info>
  <brief_title>High Protein Breakfast on Postprandial Glycemia in T2D (PBD)</brief_title>
  <acronym>PBD</acronym>
  <official_title>Effect of High Protein Breakfast on Overall Postprandial Glycemia in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas Caracas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas Caracas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that eating whey protein in breakfast will reduce overall
      postprandial glycemia in individuals with type 2 diabetes (T2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was shown that increasing protein at breakfast results in reduced overall postprandial
      glycemia in obese individuals This study was undertaken to evaluate whether compared to
      proteins like tuna, eggs and soy, the intake of whey protein in the breakfast is more
      effective to reduce overall postprandial glycemia (PPHG) in T2D individuals.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>3 month</time_frame>
    <description>Overall postprandial glycemia after breakfast, lunch and dinner</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>3 month</time_frame>
    <description>Postprandial satiety after breakfast lunch and dinner, assessed with visual analog scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>3 month</time_frame>
    <description>Body weight will be assessed every every two weeks during 3 month</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm 1-Whey protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Breakfast- other proteins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 Breakfast- low protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arm1: Whey protein</intervention_name>
    <description>Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast</description>
    <arm_group_label>Arm 1-Whey protein</arm_group_label>
    <other_name>WB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arm 2 Breakfast- other proteins</intervention_name>
    <description>Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast</description>
    <arm_group_label>Arm 2 Breakfast- other proteins</arm_group_label>
    <other_name>PB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arm 3 Breakfast- low protein</intervention_name>
    <description>Arm 3: Low protein' :The participants will consume 22 g protein at breakfast</description>
    <arm_group_label>Arm 3 Breakfast- low protein</arm_group_label>
    <other_name>LP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants: from 30 to 72 years of age

          2. BMI: 26 to 34 kg/m2)

          3. Diabetes criteria

          4. HbA1C: 7-9 % or

          5. Habitually eat breakfast

          6. Only na√Øve or treated with metformin.

          7. Not dieting and no change in body weight &gt;10 lb = 4.5 kg within the last 3 months

          8. Normal liver, kidney and thyroid function.

        Exclusion Criteria:

          1. Type 1 Diabetes

          2. Anemia (Hg &gt; 10 g/dL)

          3. Serum creatinine level &lt; 1.5 mg/dl

          4. Pulmonary disease, psychiatric, immunological, neoplastic diseases or severe diabetic
             complications, such as cardiovascular disease, cerebrovascular disease, proliferative
             diabetic retinopathy, gastroparesis or underwent bariatric surgery.

          5. Abnormal liver function tests defined as an increase by a factor of at least 2 above
             the upper normal limit of alanine aminotransferase and/or aspartate

          6. Infectious disease

          7. Pregnant women or lactating

          8. Known hypersensitivity to milk components

          9. Documented or suspected history (within one year) of illicit drug abuse or alcoholism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Jakubowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas Caracas</investigator_affiliation>
    <investigator_full_name>Daniela Jakubowicz, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

